Test–Retest Reliability of Handgrip Strength in Patients with Chronic Obstructive Pulmonary Disease

Karagiannis, Christos; Savva, Christos; Korakakis, Vasileios; Matheou, Ioanna; Adamide, Tonia; Georgiou, Andreas; Xanthos, Theodoros

doi:10.1080/15412555.2020.1808604

Cited by 17 publications

(13 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionsupporting

confidence: 77%

“…We used reliability figures from previous studies for all outcome measures and our results for MDC 95 calculations may have been impacted by this. We found for grip strength, an MDC 95 value consistent with that recently published for patients with chronic obstructive pulmonary disease 28. Transformation of raw I-RODS scores allows for adequate weighing of different disabilities on the scale,20 and exclusive consideration of the cI-RODS, as we used, and its MID appears consequently appropriate instead of raw scores, for meaningful use in clinical practice.The findings of the current analysis indicate that application of MID-defined cutoffs to define clinically relevant change, considering either the ONLS or cI-RODS, or grip strength, optimizes the interpretation of outcome measures as well as improves the detection of selfidentifying treatment-responders with CIDP.…”

supporting

confidence: 80%

See 1 more Smart Citation

Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy

2021

View full text Add to dashboard Cite

Introduction/Aim: The use of outcome measures is recommended for chronic inflammatory demyelinating polyneuropathy (CIDP). Implications of minimal important differences (MID) to ascertain responder status are unknown. The reliability of patient-reported treatment-response in relation to clinically relevant change is also unknown.Methods: We retrospectively studied 72 subjects with "definite" or "probable" CIDP evaluated at pre-specified time-intervals pre-and post-treatment. We derived MID and the minimum detectable change with 95% confidence intervals (MDC 95 ) for four scales. Scale sensitivities were determined with applicable MID-defined cutoffs (aMIDc), to detect subjects with self-identifying treatment response through a single question.Results: The use of MID was not valid for the Medical Research Council Sum Score, as MDC 95 > MID. The aMIDc for the Overall Neuropathy Limitation Score (ONLS) was 1 (sensitivity: 84.7%). The aMIDc for the centile Inflammatory Rasch-built Overall Disability Scale (cI-RODS) was 8 (sensitivity: 62.3%). The aMIDc for grip strength was 4 kg (sensitivity: 79.1%). MID-defined amelioration of any one scale among ONLS, cI-RODS, or grip strength, significantly improved sensitivity to detect treatment-responders compared with the ONLS alone

show abstract

Section: Discussionsupporting

confidence: 77%

supporting

confidence: 80%

Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy

2021

View full text Add to dashboard Cite

show abstract

“…The average result for the dominant hand was used for subsequent analysis. [27] Sample size As a pilot feasibility study, the objective was to test trial procedures, recruitment potential and feasibility and safety. The future trial arising from this pilot will aim for a medium effect size with 80% power; as suchBell et al…”

Section: Six-minute Walk Testmentioning

confidence: 99%

Feasibility of a Group-Based Telerehabilitation Intervention for Long COVID Management.

King

Byrne

Denehy

et al. 2022

Preprint

View full text Add to dashboard Cite

Background and objective: The increasing awareness of the prevalence and chronic nature of the COVID-19 disease burden requires a better understanding of effective interventions in large scale clinical trials. Telerehabilitation is effective in other chronic disease groups and the aim of this study was to assess the feasibility of a specific, group-based telerehabilitation exercise intervention for Long-COVID. Methods People with Long-COVID symptoms, defined as persistent dyspnoea, fatigue or chest pain, at least 110 days post COVID-19 diagnosis and who had not undertaken exercise training three months prior to randomisation into the trial were included. Participants were randomised to receive a twice-weekly supervised group telerehabilitation program for ten weeks or continue with usual care. Feasibility outcomes included recruitment rate, adherence, completion rate, adverse events and technological issues. Exploratory clinical outcomes including exercise capacity, fatigue and health-related quality of life were also assessed. Results 21 participants with mean age 53 ± 14 yrs, 17 of whom were not hospitalised, were recruited 365 ± 67 days after diagnosis of COVID-19. The recruitment rate was 39% of possible participants. Nine (82%) of the intervention group completed the follow-up assessments. The telerehabilitation participants completed 18 ± 2 sessions, with 100% completing 16 sessions or more. There were no adverse events and two technological problems reported for the intervention group. Conclusion Supervised group telerehabilitation appears to be feasible and safe for people with Long-COVID. A future study is required to examine the efficacy and generalizability of the supervised group-based telerehabilitation exercise intervention. Trial registration: Australian New Zealand Clinical Trials Registry (Trial ID: ACTRN12621000031864)

show abstract

“…99 routine use, both in hospital as in community healthcare settings and has been validated in COPD patients. 101 Exact cut-off values for low handgrip strength vary between studies and are dependent of appropriate reference populations. Gender, age and height specific cut-off values were published by Spruit et al, 102 whereas gender specific cut-off points have been proposed by EWGSOP2: <27 kg for men and <16 kg for women, and AWGS 2019: <28 kg for men and <18 kg for women.…”

Section: Muscle Strengthmentioning

confidence: 99%

Towards Personalized Management of Sarcopenia in COPD

Bakel¹,

Gosker²,

Langen³

et al. 2021

COPD

View full text Add to dashboard Cite

Test–Retest Reliability of Handgrip Strength in Patients with Chronic Obstructive Pulmonary Disease

Cited by 17 publications

References 66 publications

Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy

Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy

Feasibility of a Group-Based Telerehabilitation Intervention for Long COVID Management.

Towards Personalized Management of Sarcopenia in COPD

Contact Info

Product

Resources

About